Imagine taking a daily pill for less than a year, stopping the medication, and discovering that your blood pressure remains significantly lower two years later. That is what researchers observed in a small group of patients receiving an experimental treatment for a common hormonal cause of hypertension.
The findings, published in the New England Journal of Medicine, have raised the possibility that a limited course of medication could eventually spare some patients from lifelong treatment or invasive surgery. Scientists are now investigating whether the drug can actually eliminate the overactive cells responsible for the condition.
A Daily Pill Produced Unexpected Results After Treatment Ended
Researchers studying a new medication called baxdrostat have uncovered an unexpected possibility for people living with primary aldosteronism, a hormonal disorder that can cause persistent high blood pressure. Patients who received the medication for six to 12 months continued experiencing significant improvements long after they stopped taking it.
The follow-up study involved 14 patients treated at eight medical centers across the United States. All had primary aldosteronism, which occurs when the adrenal glands produce excessive amounts of a hormone called aldosterone. Researchers monitored their blood pressure and hormone levels after the medication was discontinued.
The results remained encouraging for up to two years after treatment ended. The main marker of excessive aldosterone production was still 99% lower than its original level, while participants’ blood pressure remained approximately 25 points lower on average compared with measurements taken before treatment.
Almost a quarter of the participants had normal blood pressure without taking any additional hypertension medication. This was particularly interesting because the patients had already stopped taking baxdrostat, suggesting that the treatment’s effects could persist beyond the period when the drug was actively being used.
Professor Morris Brown, a hypertension specialist at Queen Mary University of London who led the research, described the findings as exciting. Speaking about the patients who no longer required medication, Brown said, “Just under a quarter of the patients came off all treatment and had completely normal blood pressure.”
The results have attracted attention because primary aldosteronism has traditionally required long-term medication or surgery to manage. A treatment capable of producing lasting improvements after a limited course could eventually change how doctors approach certain cases of hypertension.
The Hormonal Condition Behind Millions Of Blood Pressure Cases

High blood pressure, medically known as hypertension, affects more than a billion people worldwide. Although several factors can contribute to the condition, including genetics and other medical problems, some cases are driven by excessive production of specific hormones.
Primary aldosteronism is estimated to account for approximately 5% to 10% of hypertension cases. The condition develops when the adrenal glands produce too much aldosterone, a hormone involved in regulating the body’s salt and fluid balance.
The adrenal glands are two small organs located above the kidneys. They produce hormones that help regulate several bodily functions, including blood pressure and the body’s response to stress. When aldosterone production becomes excessive, it can interfere with the normal balance of sodium and potassium.
How Excess Aldosterone Raises Blood Pressure
Aldosterone influences how the kidneys regulate sodium and potassium. When excessive amounts of the hormone circulate through the body, the kidneys retain more sodium instead of allowing it to leave through urine.
Water follows the retained sodium, increasing the amount of fluid circulating through the bloodstream. This additional fluid can raise blood pressure, creating a persistent problem that may remain difficult to control with ordinary hypertension treatments.
The condition is frequently associated with small nodules or benign growths in the adrenal glands. These growths can contain cells that produce excessive amounts of aldosterone, creating a hormonal imbalance that directly contributes to hypertension.
Why Many Patients Never Discover The Cause
One of the biggest problems with primary aldosteronism is that it can remain undiagnosed. People may be told they have high blood pressure and receive medication without discovering that excessive aldosterone production is driving their condition.
The supplied research reports that fewer than 1 in 100 people with primary aldosteronism are ever tested. Consequently, many patients could spend years managing hypertension without knowing that a specific hormonal cause may be treatable.
Identifying the condition can make a significant difference to treatment decisions. Instead of relying exclusively on medication designed to control blood pressure, doctors can investigate the hormonal problem and consider treatments that target its underlying cause.
How Baxdrostat Targets The Hormone Driving Hypertension

Baxdrostat belongs to a class of medicines called aldosterone synthase inhibitors. These medications target an enzyme known as aldosterone synthase, which the body requires to produce aldosterone.
By blocking this enzyme, baxdrostat suppresses the production of the hormone responsible for raising blood pressure in people with primary aldosteronism. This approach allows researchers to target the excessive hormone production associated with the condition.
The medication has also been investigated in studies involving people with hypertension that remains difficult to control using existing drugs. According to the supplied reference, baxdrostat received US approval earlier in 2026 for patients whose hypertension is not adequately controlled by existing medication.
However, the possibility of a lasting effect emerged from a different observation. Researchers discovered that the benefits appeared to remain long after patients completed an extended treatment course and stopped taking the drug.
Earlier investigations of aldosterone synthase inhibitors generally involved treatment periods lasting six to 12 weeks. Their outcomes were measured while participants were still taking the medication, providing information about how effectively the drugs controlled blood pressure during treatment.
The newer follow-up examined patients who had taken the medication for six to 12 months before discontinuing it. Researchers subsequently found that improvements in blood pressure and hormone measurements remained for up to two years.
This raised an important question about how the medication might be affecting the adrenal glands themselves. If the treatment changes the cells responsible for excessive aldosterone production, its benefits could potentially last much longer than the medication remains in the body.
Scientists Suspect The Treatment Could Eliminate Overactive Cells

The researchers have proposed an explanation that could account for the unusually persistent results. They suspect that prolonged suppression of aldosterone production might eventually damage or eliminate the cells responsible for producing excessive amounts of the hormone.
Professor Brown had considered this possibility long before the latest follow-up results emerged. His theory was influenced by an experiment conducted in mice approximately 20 years ago, which investigated what happened when scientists removed the gene needed to produce aldosterone synthase.
In the 2005 experiment, deleting the relevant gene caused the aldosterone-producing cells to disappear. Brown suspected that blocking the same enzyme for an extended period could potentially produce a similar effect in humans.
The Possible Role Of Reactive Oxygen Species
One proposed explanation involves molecules called reactive oxygen species. These highly active molecules can influence cellular processes, and researchers suspect that their increased production could damage the cells responsible for excessive aldosterone production.
Brown believes that suppressing aldosterone production over an extended period may trigger a rise in these molecules. If they selectively destroy the overactive cells, the adrenal glands could produce substantially less aldosterone even after treatment has ended.
Discussing the proposed mechanism, Brown said, “Those oxygen radicals are killing the cells and they disappear.” He explained that this was his current theory and that his team was investigating it through further laboratory research.
If the explanation proves correct, it could help researchers understand why some patients continued experiencing lower blood pressure long after discontinuing baxdrostat. Removing or substantially reducing the cells responsible for excessive hormone production could potentially address the underlying source of the problem.
However, the mechanism remains a hypothesis. Researchers have not yet established that the overactive cells disappear in human patients, and further investigations are necessary before they can confirm whether this process explains the clinical findings.
Why A Limited Treatment Course Could Change Medical Care

The standard treatment options for primary aldosteronism can involve long-term medication or surgical removal of the affected adrenal gland. Although these approaches can help patients manage the condition, they also come with limitations.
Medication may control excessive aldosterone activity without necessarily eliminating the cells producing the hormone. Patients can therefore face the prospect of continuing treatment over an extended period to maintain their blood pressure improvements.
Surgery offers another option for certain patients. The conventional approach involves removing the affected adrenal gland, particularly when the hormonal problem is associated with a growth that can be addressed surgically.
However, surgery is invasive, and removing an adrenal gland does not guarantee that every patient will achieve normal blood pressure. Other factors can continue contributing to hypertension even after the affected gland has been removed.
A treatment that could produce lasting improvements without surgery would offer another possibility for eligible patients. The baxdrostat findings have therefore attracted attention from researchers investigating ways to address the hormonal source of hypertension.
Potential advantages of the approach include:
- Less dependence on long-term medication: Some patients could potentially maintain normal blood pressure after completing a limited treatment course, reducing their need for additional hypertension drugs.
- An alternative to invasive surgery: If further trials confirm the results, certain patients might avoid undergoing an operation to remove an affected adrenal gland.
- Targeting the underlying hormonal problem: The treatment directly suppresses aldosterone production, addressing a specific biological cause of hypertension rather than simply measuring improvements in blood pressure.
- Possibilities for earlier treatment: Researchers believe the medication could eventually influence how doctors approach patients suspected of having primary aldosteronism.
- Potentially different treatment decisions: Patients who respond well to the medication might have another option before undergoing invasive diagnostic procedures or surgery.
These possibilities remain dependent on larger clinical trials. The current evidence is encouraging, but researchers need to establish which patients benefit and whether the effects are consistent over longer periods.
Researchers Believe The Approach Could Change Diagnosis
The findings have also raised questions about how doctors identify primary aldosteronism in patients with hypertension. If aldosterone synthase inhibitors consistently produce lasting improvements, the approach to diagnosing and treating the condition could eventually become less invasive.
Mason Freeman, a professor of medicine at Harvard University who participated in the research, believes the potential implications could be significant. He explained that the findings might change how doctors approach patients suspected of having the hormonal disorder.
“If this effect is common and very persistent then the approach to diagnosing and treating these patients is likely to dramatically change,” Freeman said.
He also suggested that doctors could potentially use an aldosterone synthase inhibitor when primary aldosteronism is initially suspected. Patients who respond well might then avoid some invasive diagnostic procedures and surgery.
That possibility is particularly interesting given how frequently the condition goes undetected. If doctors become more effective at identifying patients with excessive aldosterone production, more people could potentially receive treatment directed at the underlying hormonal problem.
However, this is a proposed future approach rather than an established medical recommendation. The research does not demonstrate that every patient with high blood pressure should receive baxdrostat, and the treatment’s potential role in diagnosis still needs to be investigated.
The distinction is important because hypertension has many different causes. A medication that targets excessive aldosterone production would be most relevant to patients whose condition is associated with that specific hormonal problem.
The ELIXIR Trial Will Investigate Whether The Effects Last

Researchers are now conducting a larger prospective clinical trial called ELIXIR to investigate whether extended aldosterone synthase inhibition can produce lasting improvements in people with primary aldosteronism.
The trial will examine whether the results observed in the original group of 14 patients can be reproduced in a larger population. This should provide stronger evidence about how consistently patients respond to treatment and whether the improvements continue after medication is discontinued.
One particularly important part of the investigation involves molecular imaging of the adrenal glands. These scans could help researchers determine whether prolonged treatment causes the aldosterone-producing cells to disappear in humans.
That evidence could help establish whether Brown’s proposed mechanism is correct. If researchers can demonstrate that the overactive cells have disappeared following treatment, it would provide a possible explanation for the lasting reduction in aldosterone production.
The larger investigation will also help clarify whether the treatment could eventually become an alternative to surgery for certain patients. Researchers need to understand how long the benefits persist and whether patients remain free from excessive hormone production after stopping medication.
Professor Brown has acknowledged that more evidence is necessary before describing the treatment as a permanent cure. In discussing the findings, he suggested that longer follow-up could eventually justify that possibility.
He also emphasized that extended aldosterone synthase inhibition is unlikely to provide a solution for most people with hypertension. Its potential benefits are specifically related to patients whose high blood pressure is driven by excessive aldosterone production.
A Promising Possibility, But A Permanent Cure Remains Unproven
The possibility of controlling a hormonal cause of high blood pressure with a limited course of medication represents an interesting development in hypertension research. For patients with primary aldosteronism, the prospect of avoiding lifelong medication or surgery could eventually offer a different treatment pathway.
However, the current findings need to be interpreted carefully. The follow-up involved only 14 patients, and researchers have not yet established that baxdrostat permanently eliminates the underlying condition.
The fact that blood pressure remained lower for up to two years is encouraging, but larger investigations must establish whether the same results occur consistently in other patients. The ELIXIR trial will be particularly important in determining whether the treatment can deliver lasting benefits and whether the suspected cellular mechanism actually occurs in humans.
For people living with high blood pressure, the research also highlights the importance of identifying its underlying cause. Some cases may involve hormonal problems that require a different treatment approach, making proper diagnosis an important part of managing the condition.
A daily pill that could eventually spare certain patients from major surgery would represent a significant medical development. For now, researchers still have to prove that the promise seen in 14 patients can become a reliable treatment for the wider population.


